ISSN 2147-9720 | E-ISSN 2148-4279
Original Article
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
1 Division of Rheumatology, University of Alberta School of Medicine and Dentistry, Edmonton, Canada  
2 Division Immunology-Rheumatology, Stanford University, Palo Alto, California, USA  
3 Department of Medicine, University of Queensland, Brisbane, Australia  
4 New York University School of Medicine, New York, USA  
5 University of Bristol, Bristol, UK  
6 ICON plc, Munich, Germany  
7 ICON plc, Houten, Netherlands  
8 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA  
9 Novartis Pharma AG, Basel, Switzerland  
Eur J Rheumatol 2018; 5: 216-223
DOI: 10.5152/eurjrheum.2018.18162
Key Words: Adalimumab, comparative effectiveness, matching-adjusted indirect comparison, ankylosing spondylitis, secukinumab
Abstract

Objective: Matching-adjusted indirect comparison was used to assess the comparative effectiveness of secukinumab 150 mg and adalimumab 40 mg in biologic-naïve patients with ankylosing spondylitis (AS) for up to 1 year.


Methods
: Pooled individual patient data from the secukinumab arms of MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375) trials (n=197) were matched against the ATLAS (NCT00085644) adalimumab population (n=208). Logistic regression analysis was used to determined weights to match for age, sex, Bath AS Functional Index, C-reactive protein levels, and previous tumor necrosis factor inhibitor therapy. Recalculated Assessment of SpondyloArthritis International Society (ASAS) 20 and 40 responses at weeks 8, 12, 16, 24, and 52 from MEASURE 1/2 (effective sample size=120) were compared with those of ATLAS. Anchored (placebo-adjusted) comparisons were possible until week 12, and unanchored (non-placebo- adjusted) comparisons were necessary thereafter.


Results
: For placebo-anchored ASAS 20 and 40 comparisons up to week 12, there were no differences between secukinumab and adalimumab. For unanchored comparisons at week 16, ASAS 20 was higher for secukinumab [odds ratio 1.60 (95% confidence interval, 1.01-2.54); p=0.047]; at week 24, ASAS 20 and 40 were higher for secukinumab [1.76 (1.11-2.79); p=0.017 and 1.79 (1.14-2.82); p=0.012, respectively]; and at week 52, ASAS 40 was higher for secukinumab [1.54 (1.06-2.23); p=0.023] than for adalimumab.


Conclusion
: There were no differences observed in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab- and adalimumab-treated patients with ankylosing spondylitis. After week 12, secukinumab demonstrated signs of greater improvement in non-placebo-adjusted ASAS 20 and 40 responses than adalimumab.
 


Cite this article as
: Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol 2018; 5: 216-23.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Medical Research and Education Association | Latest Update: 27.11.2018